Literature DB >> 8761039

Postexcitatory inhibition after transcranial magnetic single and double brain stimulation in Huntington's disease.

M Tegenthoff1, M Vorgerd, F Juskowiak, V Roos, J P Malin.   

Abstract

Postexcitatory inhibition (pI) was studied in 13 patients with different clinical forms of Huntington's disease (HD), using a transcranial magnetic single and double stimulation paradigm. We found pathological results of pI in 77% of the HD patients. A significant prolongation of pI could be demonstrated in the group of patients suffering from a classical form of HD. In contrast to these patients, those patients suffering from primary rigid HD variants exhibited a shortening of pI. These results suggest an altered excitability of the motor cortex in HD according to dysfunctions within the motor cortex-basal ganglia loop. Transcranial double stimulation was a more sensitive measure in detecting changes of cortical excitation levels than single stimulation. The interpretation of pI changes in HD has to take the clinical subtype of HD into account.

Entities:  

Mesh:

Year:  1996        PMID: 8761039     DOI: 10.1016/0924-980x(96)94645-7

Source DB:  PubMed          Journal:  Electroencephalogr Clin Neurophysiol        ISSN: 0013-4694


  3 in total

Review 1.  Hyperkinetic disorders and loss of synaptic downscaling.

Authors:  Paolo Calabresi; Antonio Pisani; John Rothwell; Veronica Ghiglieri; Josè A Obeso; Barbara Picconi
Journal:  Nat Neurosci       Date:  2016-06-28       Impact factor: 24.884

Review 2.  Cortical excitability and neurology: insights into the pathophysiology.

Authors:  Radwa A B Badawy; Tobias Loetscher; Richard A L Macdonell; Amy Brodtmann
Journal:  Funct Neurol       Date:  2012 Jul-Sep

3.  A Systematic Review of Long-Interval Intracortical Inhibition as a Biomarker in Neuropsychiatric Disorders.

Authors:  Parmis Fatih; M Utku Kucuker; Jennifer L Vande Voort; Deniz Doruk Camsari; Faranak Farzan; Paul E Croarkin
Journal:  Front Psychiatry       Date:  2021-06-02       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.